117 related articles for article (PubMed ID: 17929671)
1. A conjugate of an oligosaccharide fragment of tumor-associated ganglioside antigen with hemocyanin is a prototype antitumor vaccine.
Stepanenko RN; Tsvetkov YE; Khatuntseva EA; L'vov VL; Vlasenko RY; Nifant'ev NE; Petrov RV
Dokl Biol Sci; 2007; 415():298-301. PubMed ID: 17929671
[No Abstract] [Full Text] [Related]
2. Synthesis and immunological properties of N-modified GM3 antigens as therapeutic cancer vaccines.
Pan Y; Chefalo P; Nagy N; Harding C; Guo Z
J Med Chem; 2005 Feb; 48(3):875-83. PubMed ID: 15689172
[TBL] [Abstract][Full Text] [Related]
3. Cancer vaccines: an update with special focus on ganglioside antigens.
Bitton RJ; Guthmann MD; Gabri MR; Carnero AJ; Alonso DF; Fainboim L; Gomez DE
Oncol Rep; 2002; 9(2):267-76. PubMed ID: 11836591
[TBL] [Abstract][Full Text] [Related]
4. Synthesis of sialyl Lewis(a) (sLe (a), CA19-9) and construction of an immunogenic sLe(a) vaccine.
Ragupathi G; Damani P; Srivastava G; Srivastava O; Sucheck SJ; Ichikawa Y; Livingston PO
Cancer Immunol Immunother; 2009 Sep; 58(9):1397-405. PubMed ID: 19190907
[TBL] [Abstract][Full Text] [Related]
5. Detection of keyhole limpet hemocyanin (KLH)-specific immune responses by intracellular cytokine assay in patients vaccinated with idiotype-KLH vaccine.
Neelapu SS; Baskar S; Kwak LW
J Cancer Res Clin Oncol; 2001 Oct; 127 Suppl 2():R14-9. PubMed ID: 11768619
[TBL] [Abstract][Full Text] [Related]
6. GM3(Neu5Gc) ganglioside: an evolution fixed neoantigen for cancer immunotherapy.
Labrada M; Dorvignit D; Hevia G; Rodríguez-Zhurbenko N; Hernández AM; Vázquez AM; Fernández LE
Semin Oncol; 2018 Jan; 45(1-2):41-51. PubMed ID: 30318083
[TBL] [Abstract][Full Text] [Related]
7. Comparison of antibody titers after immunization with monovalent or tetravalent KLH conjugate vaccines.
Ragupathi G; Cappello S; Yi SS; Canter D; Spassova M; Bornmann WG; Danishefsky SJ; Livingston PO
Vaccine; 2002 Jan; 20(7-8):1030-8. PubMed ID: 11803062
[TBL] [Abstract][Full Text] [Related]
8. Ratio of IgG:IgM antibodies to sialyl Lewis(x) and GM3 correlates with tumor growth after immunization with melanoma-cell vaccine with different adjuvants in mice.
Ravindranath MH; Kelley MC; Jones RC; Amiri AA; Bauer PM; Morton DL
Int J Cancer; 1998 Jan; 75(1):117-24. PubMed ID: 9426699
[TBL] [Abstract][Full Text] [Related]
9. Conjugates of aberrant gangliosides in antiglioma vaccine: toxicological assay.
Lombardi V; Shnaar R; Minev B; Misasi R; Gitstsi Kh; Sorice M; Troncone A
Bull Exp Biol Med; 2002 Oct; 134(4):363-5. PubMed ID: 12533760
[TBL] [Abstract][Full Text] [Related]
10. Keyhole limpet hemocyanin (KLH) conjugate vaccines as novel therapeutic tools in malignant disorders.
Schumacher K
J Cancer Res Clin Oncol; 2001 Oct; 127 Suppl 2():R1-2. PubMed ID: 11768617
[No Abstract] [Full Text] [Related]
11. An anti-idiotype vaccine elicits a specific response to N-glycolyl sialic acid residues of glycoconjugates in melanoma patients.
Alfonso M; Díaz A; Hernández AM; Pérez A; Rodríguez E; Bitton R; Pérez R; Vázquez AM
J Immunol; 2002 Mar; 168(5):2523-9. PubMed ID: 11859147
[TBL] [Abstract][Full Text] [Related]
12. Allylmalonamide as a bivalent linker: synthesis of biantennary GM3-saccharide--keyhole limpet hemocyanin glycoconjugate and the immune response in mice.
Zou W; Abraham M; Gilbert M; Wakarchuk WW; Jennings HJ
Glycoconj J; 1999 Sep; 16(9):507-15. PubMed ID: 10815987
[TBL] [Abstract][Full Text] [Related]
13. Keyhole limpet hemocyanin conjugate vaccines against cancer: the Memorial Sloan Kettering experience.
Musselli C; Livingston PO; Ragupathi G
J Cancer Res Clin Oncol; 2001 Oct; 127 Suppl 2():R20-6. PubMed ID: 11768620
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity of a fucosyl-GM1-keyhole limpet hemocyanin conjugate vaccine in patients with small cell lung cancer.
Dickler MN; Ragupathi G; Liu NX; Musselli C; Martino DJ; Miller VA; Kris MG; Brezicka FT; Livingston PO; Grant SC
Clin Cancer Res; 1999 Oct; 5(10):2773-9. PubMed ID: 10537341
[TBL] [Abstract][Full Text] [Related]
15. Role of cell surface GM3 ganglioside and sialic acid in the antitumor activity of a GM3-based vaccine in the murine B16 melanoma model.
Gabri MR; Ripoll GV; Alonso DF; Gómez DE
J Cancer Res Clin Oncol; 2002 Dec; 128(12):669-77. PubMed ID: 12474053
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of tumor cell vaccine after incorporating monophosphoryl lipid A (MPL) in tumor cell membranes containing tumor-associated ganglioside.
Ravindranath MH; Brazeau SM; Morton DL
Experientia; 1994 Jul; 50(7):648-53. PubMed ID: 8033972
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the effect of different immunological adjuvants on the antibody and T-cell response to immunization with MUC1-KLH and GD3-KLH conjugate cancer vaccines.
Kim SK; Ragupathi G; Musselli C; Choi SJ; Park YS; Livingston PO
Vaccine; 1999 Nov; 18(7-8):597-603. PubMed ID: 10547417
[TBL] [Abstract][Full Text] [Related]
18. Prospects for total synthesis: a vision for a totally synthetic vaccine targeting epithelial tumors.
Keding SJ; Danishefsky SJ
Proc Natl Acad Sci U S A; 2004 Aug; 101(33):11937-42. PubMed ID: 15280546
[TBL] [Abstract][Full Text] [Related]
19. Linkage of foreign carrier protein to a self-tumor antigen enhances the immunogenicity of a pulsed dendritic cell vaccine.
Timmerman JM; Levy R
J Immunol; 2000 May; 164(9):4797-803. PubMed ID: 10779787
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activity and carrier properties of novel hemocyanins coupled to a mimotope of GD2 ganglioside.
Palacios M; Tampe R; Del Campo M; Zhong TY; López MN; Salazar-Onfray F; Becker MI
Eur J Med Chem; 2018 Apr; 150():74-86. PubMed ID: 29524730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
